RARITAN, N.J., July 22, 2021 /CNW/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced its VITROS ® Immunodiagnostic ...
Operational, performance and clinical improvements without having results interfered by common hemoglobin variants demonstrate company commitment to meet evolving customer needs Ortho Clinical ...
(RTTNews) - QuidelOrtho (QDEL) announced the FDA has granted 510(k) clearance for the VITROS hs Troponin I Reagent Pack. The assay is intended for the quantitative measurement of cardiac troponin I in ...
Jan. 11, 2006 — The US Food and Drug Administration (FDA) and Ortho-Clinical Diagnostics, Inc, have notified healthcare professionals regarding a class 1 recall of the VITROS Immunodiagnostic HBsAg ...
The FDA approved Ortho Clinical Diagnostics’ Vitros fourth-generation HIV combination test, which detects both HIV-1 and HIV-2 antibodies and the p24 antigen, which the company says allows it to ...
QuidelOrtho Corporation (QuidelOrtho), a global leader of in vitro diagnostics, announced that the US Food and Drug Administration (FDA) has granted 510(k) clearance for its VITROS hs Troponin I ...
Ortho-Clinical Diagnostics, Inc. today announced that it obtained CE Mark (Conformité Européenne) for the VITROS ® Chemistry Products HbA1c Reagent Kit, an enhanced assay to detect and monitor blood ...
The U.S. FDA has granted QuidelOrtho (QDEL) 510(k) clearance for the VITROS hs Troponin I Reagent Pack. The assay is intended for the quantitative measurement of cardiac troponin I in human plasma to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback